<SUBMISSION>
<ACCESSION-NUMBER>0001079973-08-001092
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>2
<PERIOD>20081118
<ITEMS>8.01
<ITEMS>9.01
<FILING-DATE>20081118
<DATE-OF-FILING-DATE-CHANGE>20081118
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>AspenBio Pharma, Inc.
<CIK>0001167419
<ASSIGNED-SIC>2835
<IRS-NUMBER>841553387
<STATE-OF-INCORPORATION>CO
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>001-33675
<FILM-NUMBER>081197442
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>1585 S. PERRY STREET
<CITY>CASTLE ROCK
<STATE>CO
<ZIP>80104
<PHONE>(303) 794-2000
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>1585 S. PERRY STREET
<CITY>CASTLE ROCK
<STATE>CO
<ZIP>80104
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>ASPENBIO INC
<DATE-CHANGED>20020213
</FORMER-COMPANY>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>appy_8k-111808.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>AspenBio Pharma, Inc. Form 8-K</TITLE>
</HEAD>
<BODY>




<DIV TITLE="EE+ Page Break" STYLE="page-break-after:always;"></DIV>


<!-- MARKER FORMAT-SHEET="Head Minor Center-TNR" FSL="Project" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE="3"><B>UNITED STATES <BR>SECURITIES AND EXCHANGE
COMMISSION
<BR>Washington, D.C. 20549</B> </FONT> </P>

<!-- MARKER FORMAT-SHEET="Head Minor Center-TNR" FSL="Project" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE="3"><B>FORM 8-K</B> </FONT> </P>

<!-- MARKER FORMAT-SHEET="Head Minor Center-TNR" FSL="Project" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE="3"><B>CURRENT REPORT</B> </FONT> </P>

<!-- MARKER FORMAT-SHEET="Head Minor Center-TNR" FSL="Project" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE="3"><B>Pursuant to Section 13
OR 15(d) of <BR>The Securities Exchange
Act of 1934</B> </FONT> </P>

<!-- MARKER FORMAT-SHEET="Para Large Indent Lv 0-TNR" FSL="Project" -->
<P ALIGN="Center"><FONT FACE="Times New Roman, Times, Serif" SIZE="3">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Date
of Report (Date of earliest event reported) &nbsp;&nbsp;
November 18, 2008</B> </FONT> </P>






<TABLE WIDTH="100%" BORDER="0" CELLPADDING="0" CELLSPACING="0">
<TR VALIGN="BOTTOM">
     <TH></TH>
     <TH></TH></TR>
<TR VALIGN="TOP">
     <TD WIDTH="100%" ALIGN="Center"><FONT FACE="Times New Roman, Times, Serif" SIZE="5"><U><B>AspenBio Pharma, Inc.  </B></U></FONT></TD>
</TR>
<TR VALIGN="TOP">
     <TD ALIGN="Center"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">(Exact name of registrant as specified in charter)
</FONT></TD></TR>
</TABLE>
<BR>









<TABLE WIDTH="100%" BORDER="0" CELLPADDING="0" CELLSPACING="0">
<TR VALIGN="BOTTOM">
     <TH><FONT FACE="Times New Roman, Times, Serif" SIZE="3"><U>Colorado</U> </FONT></TH>
     <TH><FONT FACE="Times New Roman, Times, Serif" SIZE="3"><U>001-33675</U> </FONT></TH>
     <TH><FONT FACE="Times New Roman, Times, Serif" SIZE="3"><U>84-155338</U> </FONT></TH></TR>
<TR VALIGN="TOP">
     <TD WIDTH="34%" ALIGN="Center"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">(State or other jurisdiction
 of incorporation)</FONT></TD>
     <TD WIDTH="33%" ALIGN="Center"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">

(Commission
File Number)</FONT></TD>
     <TD WIDTH="33%" ALIGN="Center"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">
(IRS Employer
Identification No.)
</FONT></TD></TR>
<TR VALIGN="TOP">
     <TD ALIGN="Center"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"></FONT></TD>
     <TD ALIGN="Center"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"></FONT></TD>
     <TD ALIGN="Center"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"></FONT></TD></TR>
</TABLE>

<BR>

<BR>





<TABLE WIDTH="100%" BORDER="0" CELLPADDING="0" CELLSPACING="0">
<TR VALIGN="BOTTOM">
     <TH><FONT FACE="Times New Roman, Times, Serif" SIZE="3"><U>1585 South Perry Street, Castle Rock, CO</U> </FONT> </TH>
     <TH><FONT FACE="Times New Roman, Times, Serif" SIZE="3"><U>80104</U> </FONT></TH></TR>
<TR VALIGN="TOP">
     <TD WIDTH="50%" ALIGN="Center"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">(Address of principal executive offices)</FONT></TD>
     <TD WIDTH="50%" ALIGN="Center"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">(Zip Code)</FONT></TD></TR>
</TABLE>

<BR>


<!-- MARKER FORMAT-SHEET="Head Major Center Bold 1-TNR" FSL="Project" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=3><B>Registrant&#146;s
telephone number, including area code (303) 794-2000</B> </FONT></H1>


<BR><BR>


<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Project" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Check the appropriate box below if
the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions (see General Instruction A.2. below): </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Hang Lv 5-TNR" FSL="Project" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2><FONT  size=2 FACE=WINGDINGS>o</FONT></FONT></TD>
<TD WIDTH=95%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Hang Lv 5-TNR" FSL="Project" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2><FONT  size=2 FACE=WINGDINGS>o</FONT></FONT></TD>
<TD WIDTH=95%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Hang Lv 5-TNR" FSL="Project" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2><FONT  size=2 FACE=WINGDINGS>o</FONT></FONT></TD>
<TD WIDTH=95%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) </FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Hang Lv 5-TNR" FSL="Default" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=2><FONT  size=2 FACE=WINGDINGS>o</FONT></FONT></TD>
<TD WIDTH=95%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) </FONT></TD>
</TR>
</TABLE>
<BR>
<BR><BR>




<!-- MARKER PAGE="; page: 41" -->
<HR SIZE=5 COLOR=GRAY NOSHADE>
<DIV STYLE="page-break-after:always"></DIV>

<!-- MARKER FORMAT-SHEET="Head Major Left Bold-TNR" FSL="Project" -->
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Item 8.01 &nbsp;&#151;
&nbsp;Other Events </FONT></H1>

<!-- MARKER FORMAT-SHEET="Para Indent Lv 0-TNR" FSL="Project" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
November 18, 2008, the Registrant issued a press release titled; &#147;AspenBio Pharma
Reports on FDA 510(k) Clinical Trial Progress for AppyScore, World&#146;s First
Blood-Based Diagnostic Test for Human Appendicitis&#148;.&nbsp; A copy of this press
release is attached hereto as Exhibit 99.1.  </FONT></P>


<!-- MARKER FORMAT-SHEET="Head Major Left Bold-TNR" FSL="Project" -->
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Item 9.01&nbsp;
&#151;&nbsp; Exhibits. </FONT></H1>

<!-- MARKER FORMAT-SHEET="Para (List) Hang Lv 0-TNR" FSL="Project" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH="15%" ALIGN="Center"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Exhibit<BR> No</FONT><HR WIDTH="50%" SIZE="1" COLOR="Black" ALIGN="Center"></TD>
<TD WIDTH=85%><FONT FACE="Times New Roman, Times, Serif" SIZE=2><BR>Description  </FONT><HR WIDTH="100%" SIZE="1" COLOR="Black" ALIGN="Left"></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para (List) Hang Lv 0-TNR" FSL="Project" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH="15%" ALIGN="Center"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>99.1 </FONT></TD>
<TD WIDTH=85%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Press
release dated November 18, 2008 titled, &#147;AspenBio Pharma Reports on FDA 510(k)
Clinical Trial Progress for AppyScore, World&#146;s First Blood-Based Diagnostic Test for
Human Appendicitis&#148; </FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Head Minor Center-TNR" FSL="Project" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>SIGNATURES </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Indent Lv 0-TNR" FSL="Project" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.  </FONT></P>



<TABLE WIDTH="100%" BORDER="0" CELLPADDING="0" CELLSPACING="0">
<TR VALIGN="BOTTOM">
     <TH><FONT FACE="Times New Roman, Times, Serif" SIZE="2"></FONT></TH>
     <TH><FONT FACE="Times New Roman, Times, Serif" SIZE="2"></FONT></TH>
     <TH ALIGN="Left"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">AspenBio Pharma, Inc.<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Registrant)&nbsp;<BR>&nbsp;<BR></FONT></TH>

</TR>
<TR VALIGN="TOP">
     <TD WIDTH="40%"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">Date:  November 18, 2008</FONT></TD>
     <TD WIDTH="4%"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">By:</FONT></TD>
     <TD WIDTH="56%"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">/s/ Jeffrey G. McGonegal</FONT><HR WIDTH="50%" SIZE="2" COLOR="Black" ALIGN="Left"></TD></TR>
<TR VALIGN="TOP">
     <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2"></FONT></TD>
     <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2"></FONT></TD>
     <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2">Jeffrey G. McGonegal</FONT></TD></TR>
<TR VALIGN="TOP">
     <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2"></FONT></TD>
     <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2"></FONT></TD>
     <TD><FONT FACE="Times New Roman, Times, Serif" SIZE="2">Chief Financial Officer</FONT></TD></TR>
</TABLE>
<BR>

<BR><BR><BR><BR>





<!-- MARKER PAGE="; page: 7" -->
<HR SIZE=5 COLOR=GRAY NOSHADE>


<DIV TITLE="EE+ Page Break" STYLE="page-break-after:always;"></DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>appy_8k-ex99x1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>





<!-- MARKER FORMAT-SHEET="Head Right-TNR" FSL="Default" -->
<P ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Exhibit 99.1 </FONT></P>


<!-- MARKER FORMAT-SHEET="Head Major Center Bold 1-TNR" FSL="Project" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=3>AspenBio Pharma
Reports on FDA 510(k) Clinical Trial Progress for AppyScore, <BR>World's First Blood-Based
                                  Diagnostic Test for Human Appendicitis </FONT></H1>

<!-- MARKER FORMAT-SHEET="Head Major Center Bold 1-TNR" FSL="Project" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE="3"><I>Over 700 Patients Now
Enrolled in Ongoing 800 Patient Trial</I> </FONT> </H1>





<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Project" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2><B>CASTLE ROCK, CO., November 18,
2008</B> &#151; <B>AspenBio Pharma, Inc.</B> (Nasdaq: <U>APPY</U>), an emerging
bio-pharmaceutical company dedicated to the development of novel drugs and diagnostics for
humans and animals, reported the enrollment level in the ongoing FDA 510(k) clinical trial
for AppyScore&#153;, the world&#146;s first blood-based diagnostic test for human
appendicitis exceeds 700 patients. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Project" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>As of November 17, 2008, there were
701 patients enrolled in the ongoing clinical trial in which 800 patient enrollments will
complete the study. Based upon current ongoing weekly enrollment rates, the company
anticipates achieving the goal of 800 patient enrollments within weeks. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Project" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>The study enrollment is focused on
patients arriving at hospital emergency rooms with a primary complaint of abdominal pain.
Qualified patients are further narrowed with criteria related to medical history and
duration and location of abdominal pain. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Project" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Patient test results from the
independent multicenter study are completely blind. Therefore, until the trial is
completed and data is unlocked, information concerning trial results will remain unknown
to all parties, including AspenBio, its independent Contract Research Organization
(&#147;CRO&#148;) and the participating hospitals. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Project" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Based upon the current progress, the
company expects to complete the trial later in 2008, to be followed by reporting the data
and then anticipates submitting its FDA 510(k) application early in 2009. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Project" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Following achievement of the final
study enrollment target of 800, the company estimates an additional four to six weeks will
be required for its independent medical data contractor to review and QC (quality control)
all final patient and study data, un-blind the study patient codes, and provide final data
metrics for statistical analysis. This data will be forwarded to an independent medical
statistician who will conduct statistical analysis and study results, which will then be
reported to the company for inclusion in its FDA submission. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Project" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>The company anticipates completing
its FDA 510(k) application in early 2009. Although the company has confidence in its
product, results of any blind trial can be unpredictable and inconsistent. Unforeseen
events can occur, and there are many factors which are beyond the control of the company.
Therefore, there can be no assurance AspenBio will be able to achieve its anticipated
timelines or meet expectations. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Project" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Upon completion of 800 patient
enrollments in this clinical trial, the company plans to provide an update to shareholders
that enrollment targets have been achieved. Approximately four to six weeks following
achievement of full enrollment, the company plans to issue an additional summary update to
shareholders on the final key study results as it prepares and completes its submission of
the FDA 510(k) application. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>As discussed in our press release on
October 22, 2008, advancing AppyScore and the current FDA application for our 45 minute
ELISA lab test is the company&#146;s number one priority. In addition, the company
continues to make progress on two additional formats of the appendicitis test in its
product pipeline. The two additional versions of the test, now in formal GMP development,
are designed to be approximately three times faster, providing results in approximately 15
minutes and are less labor intensive. </FONT></P>


<!-- MARKER PAGE="; page: 2" -->
<HR SIZE=5 COLOR=GRAY NOSHADE>

<DIV TITLE="EE+ Page Break" STYLE="page-break-after:always;"></DIV>



<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Project" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>AspenBio Pharma president and CEO,
Richard Donnelly, stated, <I>&#147;Completing this 800 patient trial and achieving FDA
510(k) clearance of our AppyScore appendicitis blood test is the primary focus in the
company. While the actual date of completion of the trial is too close to call, at current
rates, we are now down to just a few more weeks of enrollment, which is exciting.&#148;</I> </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Project" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>As reported earlier, results of
recent unpublished pilot data suggests that the assay performs with consistently high
sensitivity and has shown a trend of improved specificity. Further analysis of this pilot
data suggests that AppyScore in combination with other existing standard of care tests,
including white blood count (&#147;WBC&#148;) and computed tomography (&#147;CT&#148;),
may provide a significant improvement in the quality of diagnostic information available
to the physician. While results in any large blind trial cannot be assured, the company
believes the current 800 patient trial will demonstrate this improved clinical utility. </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Major Left Bold-TNR" FSL="Project" -->
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>About AspenBio Pharma,
Inc. </FONT></H1>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Project" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>AspenBio Pharma is an emerging
bio-pharmaceutical company dedicated to the discovery; development, manufacture, and
marketing of novel proprietary products, including those that enhance the reproductive
efficiency of animals and that have large worldwide market potential. The company was
originally formed to produce purified proteins for diagnostic applications and has
successfully leveraged this foundational science and technology expertise to rapidly
develop an enviable late-stage pipeline of several novel reproduction hormone analogs for
wide-ranging therapeutic use initially in bovine and equine species. AspenBio Pharma
continues to advance the development and testing of its three first-generation blood-based
human diagnostic tests designed as an aid in the diagnosis of human appendicitis. For more
information, go to <U>http://www.aspenbiopharma.com</U>. </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Major Left Bold-TNR" FSL="Project" -->
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Forward-Looking
Statements </FONT></H1>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>This news release includes
&#147;forward-looking statements&#148; of AspenBio Pharma, Inc. (&#147;APPY&#148;) as
defined by the Securities and Exchange Commission (the &#147;SEC&#148;). All statements,
other than statements of historical fact, included in the press release that address
activities, events or developments that APPY believes or anticipates will or may occur in
the future are forward-looking statements. These statements are based on certain
assumptions made based on experience, expected future developments and other factors APPY
believes are appropriate in the circumstances. Such statements are subject to a number of
assumptions, risks and uncertainties, many of which are beyond the control of APPY.
Investors are cautioned that any such statements are not guarantees of future performance.
Actual results or developments may differ materially from those projected in the
forward-looking statements as a result of many factors, including statements regarding the
ability to successfully complete the clinical trials and pivotal studies required for FDA
submission, obtain FDA approval for, cost effectively manufacture and generate revenues
from the appendicitis test as well as the animal products under this agreement and other
new products, execute agreements required to successfully advance the company&#146;s
objectives, retain the scientific management team to advance the products, overcome
adverse changes in market conditions and the regulatory environment, fluctuations in sales
volumes, obtain and enforce intellectual property rights, and realization of intangible
assets. Furthermore, APPY does not intend (and is not obligated) to update publicly any
forward-looking statements. The contents of this news release should be considered in
conjunction with the warnings and cautionary statements contained in APPY&#146;s recent
filings with the SEC. </FONT></P>



<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Project" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>For more information contact:</B><BR>
AspenBio Pharma, Inc. <BR>Gregory Pusey, Chairman <BR>Tel 303-722-4008 </FONT> </P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Project" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Investor Relations:</B> <BR>Liolios Group,
Inc. <BR>Geoffrey Plank or Ron Both <BR>Tel 949-574-3860 </FONT> </P>





<!-- MARKER FORMAT-SHEET="Center Rule" FSL="Default" -->
     <P ALIGN=CENTER>#&nbsp;#&nbsp;# </P>

<!-- MARKER FORMAT-SHEET="Head Right-TNR" FSL="Project" -->
<P ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><I>Page 3 of 3</I> </FONT> </P>



<!-- MARKER PAGE="; page: 3" -->
<HR SIZE=5 COLOR=GRAY NOSHADE>


<DIV TITLE="EE+ Page Break" STYLE="page-break-after:always;"></DIV>
</BODY>
</HTML>

</TEXT>
</DOCUMENT>
</SUBMISSION>
